# OnCo record nelitolimod (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nelitolimod/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nelitolimod" ;
  schema:name "Nelitolimod"@en ;
  schema:alternateName "SD-101"@en ;
  schema:description "Nelitolimod is an experimental immune-stimulating drug from TriSalus Life Sciences, in phase 1 trials for locally advanced pancreatic cancer and cancers in the liver."@en ;
  schema:url <https://onco.cc/drugs/nelitolimod/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://trisaluslifesci.com/pipeline/>, <https://trisaluslifesci.com/candidate-nelitolimod/>, <https://clinicaltrials.gov/study/NCT05607953>, <https://clinicaltrials.gov/study/NCT05220722>, <https://clinicaltrials.gov/study/NCT04935229> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "TLR9 agonist (immunotherapy), given through the company's pressure-enabled drug delivery devices" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/uveal-melanoma/> ;
  onco:companies <https://onco.cc/companies/trisalus-life-sciences/> ;
  onco:trials <https://onco.cc/trials/nct05607953/>, <https://onco.cc/trials/nct05220722/>, <https://onco.cc/trials/nct04935229/> .